KIKeiichi Ishida

Keiichi Ishida

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Keiichi Ishida has a total of 94 co-authors. Here are the top co-authors by number of shared publications:

  • Masahisa Masuda

    Department of Cardiovascular Surgery Chiba University Graduate School of Medicine Chiba Chiba‐shi Japan

    10 shared publications
  • Goro Matsumiya

    Department of Cardiovascular Surgery, Graduate School of Medicine Chiba University Chiba Japan

    7 shared publications
  • Nobuhiro Tanabe

    Department of Respirology, Chibaken Saiseikai Narashino Hospital, Narashino, Japan

    5 shared publications
  • Toshihiko Sugiura

    Department of Respirology, Graduate School of Medicine, Chiba University, Japan (T. Sugiura)

    5 shared publications
  • Hiroki Kohno

    Department of Cardiovascular Surgery Chiba University Graduate School of Medicine Chiba Chiba‐shi Japan

    4 shared publications
  • Seiichiro Sakao

    Department of Pulmonary Medicine, International University of Health and Welfare School of Medicine Chiba Japan

    4 shared publications

Latest Publications

  • Open Access

    Temporal trends in treatment and outcomes of patients with cardiac arrest due to pulmonary embolism: a nationwide inpatient database study

    by Keiichi Ishida, Yuji Nishimoto, Hiroyuki Ohbe, Yugo Yamashita, Makoto Mo, Yuya Kimura, Hiroki Matsui, Hideo Yasunaga

  • Open Access

    Rescue Balloon Pulmonary Angioplasty Prior to Pulmonary Endarterectomy With Concomitant Mitral Valve Plasty in High‐Risk Operable CTEPH

    by Keiichi Ishida, Nobutaka Ikeda, Seiichiro Sakao, Koichiro Sugimura, Ryuki Yamada, Norihisa Yuge, Susumu Manabe

    Pulmonary endarterectomy (PEA) is a potentially curative treatment for chronic thromboembolic pulmonary hypertension (CTEPH); however, decompensated right heart failure and concomitant cardiac procedures increase the risk of postoperative mortality. We report a case of operable CTEPH with severe mitral regurgitation causing right heart failure refractory to medical therapy. Emergent PEA combined with mitral valve plasty was considered unacceptably high risk. Although balloon pulmonary angioplasty (BPA) for CTEPH complicated by severe mitral regurgitation carries a risk of worsening pulmonary congestion, we assessed pulmonary artery wedge pressure by right heart catheterization and confirmed that it was not elevated after aggressive diuretic therapy. Therefore, a single BPA session was performed using undersized balloons, with treatment limited to a small number of lesions. This approach stabilized the patient's right heart failure without exacerbating pulmonary congestion and left‐sided heart failure. Subsequently, elective PEA combined with mitral valve plasty was successfully performed, resulting in marked improvements in pulmonary hemodynamics and clinical symptoms. This case suggests that rescue BPA followed by elective PEA with mitral valve plasty may benefit selected patients with CTEPH complicated by severe mitral regurgitation and decompensated right heart failure refractory to medical therapy.

  • Open Access

    Balloon Pulmonary Angioplasty for Chronic Thromboembolic Pulmonary Hypertension: A Nationwide Prospective Multicenter Registry in Japan (J-BPA)

    by Takeshi Ogo, Toshiro Shinke, Takumi Inami, Nobutaka Ikeda, Kohtaro Abe, Toshihiko Sugiura, Atsushi Anzai, Hiroshi Ito, Yu Taniguchi, Ichizo Tsujino, et al.

    BACKGROUND: Over the past decade, balloon pulmonary angioplasty (BPA) for chronic thromboembolic pulmonary hypertension has shown improved outcomes with procedural refinement in expert hospitals with high procedural volume. Whether the outcomes of BPA are reproducible in hospitals with limited procedural volumes remains unknown. The Japan BPA registry was designed to assess the outcomes of contemporary BPA from a nationwide perspective, including hospitals with low treatment volume. METHODS: This prospective multicenter registry enrolled 1202 consecutive patients with chronic thromboembolic pulmonary hypertension who underwent BPA at 44 hospitals between April 2018 and March 2023. We assessed the efficacy and safety of BPA and survival rates, comparing high- and low-volume hospitals based on the BPA center definition (≥50 procedures per year) from the seventh World Symposium on Pulmonary Hypertension. RESULTS: A total of 5207 procedures were performed. Thirty-five low-volume hospitals (79.5%) performed 40.8% of all BPA procedures. BPA significantly improved symptoms, clinical parameters, and hemodynamics (55.6% reduction in pulmonary vascular resistance), with 0.2% periprocedural BPA-related mortality. Severe lung injury (0.3%), balloon overdilatation (0.67%), and mechanical ventilation (0.3%) were less common in high-volume hospitals than in low-volume hospitals (1.3%, 1.7%, and 1.5%, respectively; P <0.001). In the Kaplan-Meier analysis, the survival rate of all patients at 3 years was 94.7% (95% CI, 92.5%–96.3%). Multivariable Cox regression analysis showed an increased mortality risk with higher right atrial pressure, and high-volume hospitals were associated with a reduced mortality risk. CONCLUSIONS: This nationwide registry demonstrated the outcomes of contemporary BPA in patients with chronic thromboembolic pulmonary hypertension. No significant differences were observed in efficacy and periprocedural mortality between low- and high-volume hospitals. However, the significantly lower rate of severe complications in high-volume hospitals indicates that BPA may be safer in high-volume hospitals.


  • Short-term outcomes of thrombolysis versus surgical pulmonary embolectomy in patients with high-risk pulmonary embolism

    by Keiichi Ishida, Yuji Nishimoto, Hiroyuki Ohbe, Nobutaka Ikeda, Toshihiko Sugiura, Rika Suda, Nobuhiro Tanabe, Makoto Mo, Yuya Kimura, Hiroki Matsui, et al.


  • Open Access

    Clinical significance of lung cross‐sectional area measured by computed tomography in chronic thromboembolic pulmonary hypertension: The correlation with pulmonary hemodynamics and the limitations

    by Ayaka Kuriyama, Hajime Kasai, Toshihiko Sugiura, Jun Nagata, Akira Naito, Ayumi Sekine, Ayako Shigeta, Seiichiro Sakao, Keiichi Ishida, Goro Matsumiya, et al.

    The percentage cross‐sectional area of the lung under five (%CSA) is the percentage of pulmonary vessels with 2 area relative to the total lung area on computed tomography (CT). The extent that %CSA is related to pulmonary hemodynamics in patients with chronic thromboembolic pulmonary hypertension (CTEPH) is unclear, as is the effect of pulmonary endarterectomy (PEA) on %CSA. Therefore, we aimed to evaluate the clinical significance of %CSA in patients with CTEPH. We studied 98 patients (64 females, mean age 62.5 ± 11.9 years), who underwent CT with %CSA measurement and right heart catheterization (RHC). Patients were classified into groups based on eligibility for PEA. We compared the %CSA with pulmonary hemodynamics measured by RHC in various groups. In 38 patients who underwent PEA, the relationship between %CSA and pulmonary hemodynamics was also evaluated before and after PEA. Significant correlations between %CSA and pulmonary vascular resistance, and compliance, and pulmonary artery pulse pressure were observed in all patients. Pulmonary hemodynamics in the patients who underwent or were eligible for PEA showed a significant correlation with %CSA. Additionally, %CSA was significantly lower in the postoperative than in the preoperative group. There was no correlation between changes in %CSA and pulmonary hemodynamics before and after PEA. Furthermore, %CSA did not correlate significantly with prognosis. %CSA may reflect pulmonary hemodynamics in CTEPH with central thrombosis. Furthermore, %CSA was reduced by PEA postoperatively. However, %CSA is not a prognostic indicator, its clinical usefulness in CTEPH patients is limited, and further validation is required.

  • Open Access

    Impact of residual pulmonary hypertension on long‐term outcomes after pulmonary endarterectomy in the modern era

    by Keiichi Ishida, Hiroki Kohno, Kaoru Matsuura, Toshihiko Sugiura, Takayuki J. Sanada, Akira Naito, Ayako Shigeta, Rika Suda, Ayumi Sekine, Masahisa Masuda, et al.

    Residual pulmonary hypertension (PH) negatively impacts long‐term results following pulmonary endarterectomy (PEA) for chronic thromboembolic pulmonary hypertension (CTEPH). We sought to reveal whether modern PH therapy with PH‐targeted medicine and balloon pulmonary angioplasty (BPA) improved long‐term results of residual PH after PEA. Long‐term findings of 80 patients who survived PEA between 2011 and 2019 were retrospectively investigated. One month after PEA, 30 patients developed residual PH defined as mean pulmonary artery pressure (mPAP) ≥25 mmHg, of whom 23 were treated by PH‐targeted medicine and 9 by BPA. Patients with residual PH acquired considerably better functional status and exercise capacity after PEA, however, exhibited significantly worse survival rates than those without. Eleven patients died during follow‐up: 8 patients with residual PH and 3 controls. Among patients with residual PH, the deceased had a significantly lower %decrease in mPAP from 1 month to 1 year following PEA (7.4 [−32.6 to 8.0] % vs. 10.4 [3.7−27.8] %, p = 0.03) and higher mPAP at 1 year following PEA (39.5 [33.25−42.5] vs. 27 [26−34] mmHg, p < 0.01) despite PH‐targeted medicine than the survived. No patients passed away from right heart failure, and there was no difference between the groups in CTEPH‐related mortality. Modern PH therapy was used to address the majority of residual PH. Long‐term survival after PEA was negatively impacted by residual PH, but it appeared that long‐term mortality was also correlated with unrelieved residual PH despite PH‐targeted medicine. Modern PH therapy may have enhanced functional status and excercise capacity, and averted fatal right heart failure.


  • Modification of pulmonary endarterectomy to prevent neurologic adverse events

    by Keiichi Ishida, Hiroki Kohno, Kaoru Matsuura, Michiko Watanabe, Toshihiko Sugiura, Takayuki Jujo Sanada, Akira Naito, Ayako Shigeta, Rika Suda, Ayumi Sekine, et al.

    Purpose Neurologic adverse events (NAEs) are a major complication after pulmonary endarterectomy (PEA) performed under periods of deep hypothermic circulatory arrest (HCA) for chronic thromboembolic pulmonary hypertension. We modified the PEA strategy to prevent NAEs and evaluated the effectiveness of these modifications. Methods We reviewed the surgical outcomes of 87 patients divided into the following three groups based on the surgical strategy used: group S (n = 49), periods of deep HCA with alpha-stat strategy; group M1 (n = 19), deep HCA with modifications of slower cooling and rewarming rates and the pH–stat strategy for cooling: and group M2 (n = 13), multiple short periods of moderate HCA. Results PEA provided significant improvement of pulmonary hemodynamics in each group. Sixteen (29%) of the 49 group S patients suffered NAEs, associated with total circulatory arrest time (cutoff, 57 min) and Jamieson type I disease. The Group M1 and M2 patients did not suffer NAEs, although the group M1 patients had prolonged cardiopulmonary bypass (CPB) and more frequent respiratory failure. Conclusions NAEs were common after PEA performed under periods of deep HCA. The modified surgical strategy could decrease the risk of NAEs but increase the risk of respiratory failure. Multiple short periods of moderate HCA may be useful for patients at risk of NAEs.


  • Heterogeneity of Lung Density in Patients With Chronic Thromboembolic Pulmonary Hypertension (CTEPH)

    by Akira Nishiyama, Naoko Kawata, Hajime Yokota, Koichi Hayano, Shin Matsuoka, Ayako Shigeta, Toshihiko Sugiura, Nobuhiko Tanabe, Keiichi Ishida, Koichiro Tatsumi, et al.


  • Loss Evaluation of Low-Loss Boost-Chopper Circuit for Inverter Systems in Air Conditioners

    by Keiichi Ishida, Yohei Kubota, Masaki Kanamori, Takahisa Endo, Tetsuji Yamashita, Hidetoshi Kanazawa


  • Open Access

    A prospective, randomized study of inhaled prostacyclin versus nitric oxide in patients with residual pulmonary hypertension after pulmonary endarterectomy

    by Shinichiro Abe, Keiichi Ishida, Masahisa Masuda, Hideki Ueda, Hiroki Kohno, Kaoru Matsuura, Yusaku Tamura, Michiko Watanabe, Goro Matsumiya

    Objectives Pulmonary endarterectomy (PEA) is an effective treatment for chronic thromboembolic pulmonary hypertension (CTEPH), but postoperative residual hypertension leads to in-hospital mortality. Inhaled epoprostenol sodium (PGI2) and NO are administered for pulmonary hypertension after cardiothoracic surgery. This prospective study provides the first comparative evaluation of the effects of inhaled PGI2 and NO on pulmonary hemodynamics, systemic hemodynamics, and gas exchange in patients developing residual pulmonary hypertension after PEA. Methods Thirteen patients were randomized to receive either NO (n = 6) or PGI2 (n = 7) inhalation when pulmonary hypertension persisted after weaning from cardiopulmonary bypass. Hemodynamic and respiratory variables were measured before inhalation of the agent (T0); 30 min (T1), 3 h (T2), and 6 h after inhalation (T3); and the next morning (T4). The NO dose was started at 20 ppm and gradually tapered until extubation, and PGI2 was administered at a dose of 10 ng kg−1 min−1. Results In both groups, mean pulmonary artery pressure (PAP) and pulmonary vascular resistance (PVR) significantly decreased over time until T4 (mean PAP: p < 0.0001; PVR: p = 0.003), while mean systemic arterial blood pressure significantly increased (p = 0.028). There were no significant between-group differences in patient characteristics, cardiac index, left atrial pressure, or ratio of arterial oxygen tension to fraction of inspired oxygen. There were no in-hospital deaths. Conclusions Both inhaled PGI2 and NO significantly reduced PAP and PVR without adverse effects on systemic hemodynamics in patients who developed residual pulmonary hypertension after PEA. Inhaled PGI2 can be offered as alternative treatment option for residual pulmonary hypertension.